A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2016-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-016-3167-7PMID 27744565
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics, metabolism, and excretion of 14C-labeled belinostat in patients with recurrent or progressive malignancies

  2016cited by this paper
• A phase I/Ib, open-label, dose-finding study to evaluate safety, pharmacodynamics, and efficacy of pembrolizumab (MK-3475) in combination with vorinostat in patients with advanced renal or urothelial cell carcinoma.

  2016cited by this paper
• Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase.

  2015cited by this paper
• Bortezomib and belinostat inhibit renal cancer growth synergistically by causing ubiquitinated protein accumulation and endoplasmic reticulum stress.

  2015cited by this paper
• A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes.

  2015cited by this paper
• Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.

  2015cited by this paper
• Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling

  2015cited by this paper
• Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

  2015cited by this paper
• A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma

  2015cited by this paper
• Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review

  2015cited by this paper
• Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer

  2014cited by this paper
• Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo

  2014cited by this paper
• Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells

  2014cited by this paper
• Belinostat: First Global Approval

  2014cited by this paper
• PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.

  2013cited by this paper
• LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.

  2013cited by this paper
• RETRACTED ARTICLE: Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer

  2013cited by this paper
• Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer

  2013cited by this paper
• Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment

  2013cited by this paper
• HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

  2012cited by this paper
• Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer

  2012cited by this paper
• Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.

  2011cited by this paper
• The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models

  2011cited by this paper
• Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF‐κB and Bim

  2011cited by this paper
• Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.

  2011cited by this paper
• Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.

  2011cited by this paper
• The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines

  2010cited by this paper
• Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

  2010cited by this paper
• Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma

  2010cited by this paper
• Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy—California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial

  2008cited by this paper
• Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer

  2008cited by this paper
• A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

  2008cited by this paper
• Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells

  2008cited by this paper
• The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo

  2007cited by this paper
• Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101

  2007cited by this paper
• The histone deacetylase inhibitor, PXD101, potentiates bortezomib‐induced anti‐multiple myeloma effect by induction of oxidative stress and DNA damage

  2007cited by this paper
• Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies

  2006cited by this paper
• Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

  2005cited by this paper
• Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.

  2003cited by this paper
• Molecular sequelae of histone deacetylase inhibition in human malignant B cells.

  2003cited by this paper
• Journal of Translational Medicine the Histone Deacetylase Inhibitor Belinostat (pxd101) Suppresses Bladder Cancer Cell Growth in Vitro and in Vivo

  year unknowncited by this paper

• Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups

  2025cites this paper
• The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers

  2024cites this paper
• Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies

  2023cites this paper
• Histone deacetylase inhibitor belinostat regulates metabolic reprogramming in killing KRAS‐mutant human lung cancer cells

  2023cites this paper
• Histone Deacetylases in Kidney Physiology and Acute Kidney Injury.

  2020cites this paper
• Epigenetic Regulation of MDR1 and BCRP Transporters by HDAC Inhibition

  2020cites this paper
• Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy

  2020cites this paper
• lnhibitori histonskih deacetilaza kao protutumorski lijekovi

  2020cites this paper
• Epigenetic Regulation of MDR1 and BCRP Transporters by HDAC Inhibition.

  2020cites this paper
• Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

  2019cites this paper
• Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin-Induced CYP3A4 and MDR1 Gene Expression

  2019cites this paper
• Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability

  2019cites this paper
• A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction

  2019cites this paper
• Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas

  2019cites this paper
• Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma

  2018cites this paper